

CURRICULUM VITAE

PROF. ANGELIKI-VIKTORIA ROUSSAKI-SCHULZE

UNIVERSITY OF THESSALY AND UNIVERSITY GENERAL HOSPITAL OF LARISSA, GREECE

University General Hospital of Larissa, Mesourlo, 41110 Larissa, Greece. Telephone 2413502788, Email roussaki@med.uth.gr

Larissa 29-10-2019

PERSONAL INFORMATION

Married Surname: Roussaki-Schulze

Maiden Surname: 1) Roussaki
2) From 05-05-2000 Kotoula-Roussaki (adoption from my stepfather)

First Name: Angeliki-Viktoria

Date of birth: 20-07-1957

Place of birth: Athens, Greece

Professional address and phone: University General Hospital of Larissa, Mesourlo, 41110 Larissa, P.O. Box 1425, Greece.
Phone +302413502788

Mobile phone: +306977262628 and +306946005525

Marital status: Widowed with two children (boys, twins)

Languages: Greek, German, Italian, English (Certificate of English Proficiency with very good, Pierce College-American Junior College)

EDUCATION

PRIMARY-SECONDARY EDUCATION

1963-1969: Elementary School in Athens

1969-1975: High School in Athens (American Junior College-Pierce College)

24/06/75: Graduated from Secondary School

TERTIARY EDUCATION

- 1/10/1975 - 30/09/1978: Medical School, University of Padova (Medicina e Chirurgia, Università di Padova), Italy
- 01/10/1978 - 08/11/ 1983: Medical School, University of Athens (National and Kapodistrian University of Athens), Greece.
- 08/11/1983: Graduated from University with “Very Good”.

MEDICAL LICENSE

- 10/01/1984: Medical License in Greece (protocol number 26537, 13-12-1983)
- 30/03/88: Medical License of Dermatology-Venereology.
- 22/12/1988 Medical License in Germany (Approbationsurkunde)
- 18/09/1990: License to use Laser in Medicine, in Germany.
- 10/09/1992: **Doctoral Thesis** (Albert-LudwigsUniversity, Freiburg i. Br.,Germany): Cellular Infiltration of viral papillomas, condylomataacuminata before and during the therapy with recombinant-Interferon- α -2a, recombinant-Interferon- γ , Isoprinosine.

POSTGRADUATE STUDIES

- 13/01/1984-15/01/1988: Resident (Assistenzarzt) at the Dermatological Clinic of Albert-LudwigsUniversity, Freiburg i. Br. Germany (Prof. Dr. E. Schöpf).

- 17/09-18/09/1990: Training to use Laser, in the Laser-Medizin-Zentrum GmbH, Berlin, Prüfstelle für Medizinische Geräte an der Freien Universität Berlin, Germany. License to use Laser in Medicine, Germany.
- 01/02/89-31/01/94: Research Assistant Doctor (Wissenschaftlicher AngestellterArzt) at the Dermatological Clinic, University of Hamburg, Germany (Prof. Dr. Dr. Ring). Specially training in the ambulance for sexually transmitted diseases and viral infections of the skin.
- 01/02/1994-28/02/1994: Visiting Doctor (Gastarzt) at the Dermatological Clinic University of Hamburg, Germany (Prof. Dr. Dr. Ring).
- 01/03/1994-31/08/1994: Research Assistant Doctor (Wissenschaftlicher AngestellterArzt) at the Dermatological Clinic, Municipal Hospital of Darmstadt, Academical Hospital of University Johann Wolfgang Goethe, Frankfurt Main, Germany (Prof. Dr. Hagedorn).

PROFESSIONAL EXPERIENCE

- 01/02/89-31/01/94: Research Assistant Doctor (Wissenschaftlicher AngestellterArzt) at the Dermatological Clinic, University of Hamburg, Germany (Prof. Dr. Dr. Ring). Specially training in the ambulance for sexually transmitted diseases and viral infections of the skin.
- 01/02/1994-28/02/1994: Visiting Doctor (Gastarzt) at the Dermatological Clinic University of Hamburg, Germany (Prof. Dr. Dr. Ring).
- 01/03/1994-31/08/1994: Research Assistant Doctor (Wissenschaftlicher AngestellterArzt) at the Dermatological Clinic, Hospital Darmstadt, Germany (Prof. Dr. Hagedorn).
- 29/5/1995-13/1/1998 Private Practice as Dermatologist-

Venereologist in Athens, Greece.

- 22-10-2018- 23/10/2018: **Associate Professor of Dermatology**, of Medical Department, of School of Health Sciences, of the University of Thessaly, Greece.
- Since 12/11/1998 Director of the Dermatology Department of the University General Hospital of Larissa, Greece.
- From 17-10-2013 until now: Private Practice as Dermatologist-Venereologist. Working with an interdisciplinary team in Agia, Larissa, Greece.
- From 11/08/2014 until now: Private Practice as Dermatologist-Venereologist, Nikea-Larissa, Greece.
- From 23-10-2018 **A' grade Professor of Dermatology** of Medical Department, of School of Health Sciences, of the University of Thessaly, Greece.

TEACHING EXPERIENCE

UNDERGRADUATE COURSES

- 01/09/1997- 13/01/1998: Teaching Dermatology and Venereology at the University of Thessaly.
- From February 1998 until now: Head of teaching medical students in Dermatology-Venereology.

POSTGRADUATE COURSES

- From 2003 until now: Head of teaching and training residents of the Department of Dermatology, University General Hospital of Larissa, Greece.
- 08/2006-now Training of General Practitioners residents during their practice of two month at the Department of Dermatology, University General Hospital of Larissa, Greece.
- 11/2007-Now Training of Occupational Physicians residents during their practice of two month at the Department of Dermatology, University General Hospital of Larissa, Greece.
- 8/2010 –Now Teaching in Seminars: “Pathological and Surgical Nursing Specialty” within the course of Dermatology.

SUPERVISOR OF DOCTORAL THESIS

1. Undertaking a doctoral degree: 6
2. Completed a doctoral thesis: 7

POSTGRADUATE STUDIES, DIPLOMA THESIS, MEMBER OF COMMITTEE

1. Undertaking a diploma thesis: 4
2. Completed a diploma thesis: 3

PARTICIPATION IN CLINICAL TRIALS AS INVESTIGATOR: 21

PUBLICATIONS

Citations 969

h-index 18

i10-index 29

FULL PUBLICATIONS IN INTERNATIONAL JOURNALS

1. Gross G, Ikenberg H, **Roussaki A**, Drees N, Schoepf E: Systemic treatment of condylomata acuminata with recombinant interferon- α -2a: low dose superior to the high dose regimen. *Chemotherapy* 1986; 32: 537-541.
2. Gross G, **Roussaki A**, Ikenberg H, Drees N: Interferon- α bei Condylomata acuminata und juvenilem Diabetes mellitus. *Deutsche Medizinische Wochenschrift* 1986, 111 Jg. Nr. 36: 1351-1355.
3. Gross G, **Roussaki A**, Schoepf E, De Villiers E-M, Papendick U: Successful treatment of condylomata acuminata and bowenoid papulosis with subcutaneous injections of low dose recombinant interferon- α . *Arch. Dermatol.* July 1986; Vol 122: 749-750.
4. Gross G, **Roussaki A**, Pfister H: Die postoperative Interferon-Hydrogel-Behandlung. Methode zur erfolgreichen Therapie chronisch persistierender Riesenkondylome bei einer immundefekten Patientin mit Morbus Hodgkin. *Hautarzt* 1988; 39: 684-687.
5. Gross G, Ellinger K, **Roussaki A**, Fuchs P.G, Peter H.H, Pfister H. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: Characterization of a new Papillomavirus type and interferon treatment. *J. Inv. Dermatol.* Vol. July 1988; 91; No.1: 43-48.

6. Vanscheidt W, Wokalek H, Vanscheidt E, **Roussaki A**, Schoepf E. Ulceracrusis bei Faktor XIII-Mangel. *Phlebol. u. Proktol.* 1988; 17: 113-115.
7. Gross G, **Roussaki A**, Ikenberg H. Interferon-alpha Therapie bei genitalen Warzen erfolglos bei Haschischrauchern. *Z Blatt Haut-u. GeschlKrankh.* 1989;156, 693.
8. Gross G, **Roussaki A**, Papendick, U. Efficacy of interferons on Bowenoid Papulosis and other precancerous lesions. *J Invest. Dermatol.* December 1990; Vol. 95; Number 6; Supplement: 152S-157S.
9. Gross G, **Roussaki A**, Ikenberg H, Drees, N. Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption. *Dermatologica* 1991; 183: 203-207.
10. Recombinant Interferon-Gamma in Condylomata Acuminata Study Group included the following: Gross G, Kowalzik L, **Roussaki A**, Degen K W, Fierlbeck G, Hilgarth H, Ruffli T, Stetter C, Brzoska J. Recombinant Interferon gamma in condylomata acuminata. *JAMA*, November 20, 1991; Vol. 226; No 19: 2706.
11. Gross G, **Roussaki A**, Bauer S, Wiegand M, Mescheder A: Systemically administered interferon-alfa-2a prevents recurrence of condylomata acuminata following CO2-laser ablation-the influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. *Genitourinary Medicine* Feb. 1996; 72 (1): 71.
12. Gross G, **Roussaki A**, Brzoska J. Recalcitrant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO2-laser and natural interferon beta gel. *Acta DermVenereol (Stockh)* 1998, 78: 309.
13. Gross G, Rogozinski T, Schoefer H, Jablonska S, **Roussaki A**, Woehr C, Brzoska J: Recombinant Interferon Beta Gel as an adjuvant in the treatment of recurrent genital warts, result of a placebo-controlled double-blind study in 120 patients. *Dermatology* 1998, 196: 330-334.
14. **Roussaki-Schulze A**, Klimi E, Zafiriou E, Aroni K, Mpaltopoulos A, Aravantinos E, Melekos M: Granuloma faciale associated with adenocarcinoma of the prostate. *International Journal of Dermatology*; Volume 41; Number 12, December 2002: 901-902.
15. Rallis E, Nasiopoulou A, Kouskoulis C, **Roussaki-Schulze A**, Koumantaki E, Arvanitis A. Successful treatment of genital and facial psoriasis with tacrolimus ointment 0,1%. *Drugs Exp. Clin. Res.* 2005; 31(4): 141-145.

16. **Roussaki-Schulze A V**, Kouskoulis C, Rammos C, Rallis E, Kontos F, Zafiriou E, Gross G. Identification of Human Papilloma virus (HPV) DNA in melanoma biopsy specimens of Greek population. *Int. J. clin. Pharm. Res.* 25(3), 2005: 145-150.
17. Rallis E, Nasiopoulou A, Kouskoulis C, **Roussaki-Schulze A**, Koumantaki E, Arvanitis A. Oral administration of cyclosporin A in patients with severe alopecia areata. *Int. J. Tissue react.* 2005; 27(3): 107-110.
18. **Roussaki-Schulze AV**, Kouskoulis C, Petinaki E, Klimi E, Zafiriou E, Galanos A, Rallis E. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. *Int. J. clin. Pharm. Res.* 25(4), 2005: 169-173.
19. **Roussaki-Schulze AV**, Kouskoulis C, Klimi E, Zafiriou E, Galanos A, Rallis E. Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrowband UVB in the treatment of psoriasis. *Drugs exptl. clin. Res.* 31(5-6), 2005:169-174.
20. **Roussaki-Schulze A V**, Rammos C, Rallis E, Terzis A, Archontonis N, Sarmanta A, Klimi E, Zafiriou E. Increasing incidence of melanoma in cenral Greece: a retrospective epidemiological study. *Int. J. Tissue react.* 27(4), 2005: 173-179.
21. Zafiriou E, Angelopoulos N V, Zinzaras E, Rallis E, **Roussaki-Schulze A V**. Psychiatric factors in patients with sensitive skin. *Drugs Exp. Clin. Res.* 2005; 31 Suppl. : 25-30.
22. **Roussaki-Schulze A V**, Zafiriou E, Nikoulis D, Klimi E, Rallis E. Objective biophysical findings in patients with sensitive skin. *Drugs Exp. Clin. Res.* 2005; 31 Suppl. : 17-24.
23. Ioannou M, Sourli F, Mylonis I, Barbanis S, Papamichali R, Kouvaras E, Zafiriou E, Siomou P, Klimi E, Simos G, **Roussaki-Schulze AV**, Koukoulis G. Increased HIF-1 alpha immunostaining in psoriasis compared to psoriasisiform dermatitides. *J Cutan Pathol*, 2009: 36: 1255-1261.
24. Vladeni S, Petinaki E, **Roussaki-Schultze AV**. Hair characteristics and lice infestation. Data from schoolchildren in Greece. *J Eur Acad Dermatol Venereol*, 2011, 25: 118-119.
25. Vladeni S, Petinaki E, Maniatis A, **Roussaki-Schulze AV**. Prevalence of pediculosis capitis among schoolchildren in Greece and risk factors. A questionnaire survey. *Pediatric Dermatology*, 2009 Nov-Dec; 26 (6):701-705.
26. Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Krüger-Krasagaki S, Tosca A, Patsatsi A, Sotiriadis D, Mamuris Z, **Roussaki-Schulze A**. Pharmacogenetic analysis of TNF,

TNFRSF1A and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. *Mol Diagn Ther*, 2012 Feb 1; 16(1):29-34.

27. Papadopoulou MC, Tsiouri I, Salta-Stankova R, Drakou A, Rousas N, **Roussaki-Schulze AV**, Giannoukas AD. Multidisciplinary lymphedema treatment program. *Int J Low Extrem Wounds*, 2012 Mar; 11(1):20-7.
28. Kyrgias G, Kostopoulou E, Zafiriou E, Zygogianni A, Skarlatos J, **Roussaki-Schulze AV**, Theodorou K. Hidradenocarcinoma of the temporal area successfully treated with concomitant electrochemotherapy and radiotherapy. *Head Neck Oncol*. 2013 Feb 06;5(2):14.
29. Vasilopoulos Y, Sourli F, Zafiriou E, Klimi E, Ioannou M, Mamuris Z, Simo sG, Koukoulis G, **Roussaki-Schulze A**. High serum levels of HIF-1^α in psoriatic patients correlate with an over-expression of IL-6. *Cytokine*. 2013 Apr;62(1):38-9.
30. Vasilopoulos Y, Sarri C, Zafiriou E, Patsatsi A, Stamatis C, Ntoumou E, Fassos I, Tsalta A, Karra A, **Roussaki-Schulze A**, Sotiriadis D, Mamuris Z, Sarafidou T. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. *Pharmacogenomics J*. 2014 Dec;14(6):523-5.
31. Mendrinou E, Zafiriou E, Patsatsi A, **Roussaki-Schulze A**, Sotiriadis D, Mamours Z, Sarafidou T, Vasilopoulos Y. Cyp3A*5 is not a pharmacogenetics marker for cyclosporine treatment response in psoriasis. *J Pharma Pharmacovigilance* 2015, 1(1): 002.
32. Sarrou S, Liakopoulos A, Chasioti M, Foka A, Fthenakis G, Billinis C, Spyrou V, Pantelidi K, **Roussaki-Schulze A**, Lachanas V, Makaritsis K, Skoulakis C, Daikos G, Dalekos G, Spiliopoulou I, Petinaki E. Dissemination of Methicillin-Susceptible CC398 *Staphylococcus aureus* Strains in a Rural Greek Area. *PLoS One*. 2015 Apr 2;10(4):e0122761. doi: 10.1371/journal.pone.0122761. eCollection 2015
33. Vageli D, Exarxou A, Zafiriou E, Doukas P, **Roussaki-Schulze A**. Effect of TNF- α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques. *Exp Ther Med*. 2015 Oct;10(4):1573-1577.
34. Kitsioulis NA, Xepapadaki P, **Roussaki-Schulze AV**, Papadopoulos N, Zafiriou E. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria. *Int Arch Allergy Immunol*. 2017;172(3):161-166.

35. Sarri C A, **Roussaki-Schulze A**, Vasilopoulos Y, Zafiriou E, Patsatsi A, Stamatis C, Gidarokosta P, Sotiriadis D, Sarafidou T, Mamuris Z. Netherton Syndrome: A Genotype-Phenotype Review. *Mol Diagn Ther.* 2017 Apr;21(2):137-152.
36. Mendrinou E, Patsatsi A, Zafiriou E, Papadopoulou D, Aggelou L, Sarri C, Mamuris Z, Kyriakou A, Sotiriadis D, **Roussaki-Schulze A**, Sarafidou T, Vasilopoulos Y. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF α inhibitors. *Pharmacogenomics J.* 2017 Jun;17(3):237-241.
37. Mavropoulos A, Zafiriou E, Liaskos C, Alexiou I, **Roussaki-Schulze A**, Vlychou M, Katsiari C, Bogdanos DP, Sakkas LI. IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFN γ -producing T cells. *Clin Immunol.* 2017 Apr 28.
38. Mastrafsi S, Sarrou S, Pandelidi K, Skoulakis A, **Roussaki A** and Petinaki E. Antimicrobial resistance and molecular characterization of staphylococcus aureus strains causing skin and soft tissue infections in Greek adults. *Acta scientific microbiology* 2018, 1 (2): 24-26.
39. Mavropoulos A, Zafiriou E, Simopoulou T, Brotis A, Liaskos C, **Roussaki-Schulze A**, Katsiari C, Bogdanos DP and Sakkas L. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. <https://academic.oup.com/rheumatology>, 2019, doi:10.1093/rheumatology/kez204.

ABSTRACTS IN INTERNATIONAL JOURNALS

1. Gross G, **Roussaki A**, Brzoska J: Low doses of systemically administered recombinant interferon-gamma effective in the treatment genital). *J Invest. Dermatol.* February 1988; Vol. 90, No. 2: 242.
2. Gross G, Ikenberg H, **Roussaki A**, Kunze B, Drees N: Does the Papillomavirus DNA persist in the epithelium after successful treatment of genital warts with subcutaneous injections of recombinant interferon alpha?(Abstract) *J. Inv. Dermatol.* February 1988; Vol. 90; No. 2: 242.
3. Gross G, **Roussaki A**: Efficacy of interferons on bowenoid papulosis and other precancerous lesions. *J Invest. Dermatol.* October 1989; Vol. 93; No. 4: 553 .
4. Gross G, Degen W, Hilgarth M, Kowalzik L, **Roussaki A**, Rufli T, Schoefer H, Brzoska J: Recombinant interferon-gamma in genital warts: results of a multicenter placebo controlled clinical trial. *J Invest. Dermatol.* October 1989; Vol. 93; No. 4: 553.
5. Gross G, **Roussaki A**, Pfister H: Adjuvant postsurgical interferon alfa-gel therapy for recalcitrant genital warts in immunocompromised patients. (Abstract) *J Invest. Dermatol.* October 1989; Vol. 93; No. 4: 553.

6. Gross G, Degen W, Hilgarth M, Kowalzik L, **Roussaki A**, Ruffli T, Schoefer H, Brzoska J: Recombinant interferon-gamma in genital warts: results of a multicenter placebo controlled clinical trial. J Interferon Res. October 1989; Vol. 9; Suppl. 2: S131.
7. Gross G, **Roussaki A**: Effect of interferon beta gel on vulvar and penile lichen sclerosus. (Abstract) Annals of Oncology 1990; Supplement to Volume 1: 94 .
8. GrossG, **RoussakiA**, BrzoskaJ: Topicalinterferonbetagelasadjuvanttherapyinimmunocompromisedpatientswithrecurrentgenitalwarts. JInterferonRes. 1990; 10; Suppl 1:112.
9. Gross G, **Roussaki A**, Mausch HE, Ring J: HPV6-positivegenitaleCondylomata acuminata bei einem 4-jaerigen Maedchen und HPV6-positive Riesencondylome bei einer 63-jaerigen Grossmutter. Zentralblatt Haut und Geschlechtskrankheiten 1993;162, 231.
10. Gross G, Rogozinski T, Schoefer H, Jablonska S, **Roussaki A**, Wolf H, Stetter C, Brzoska J: Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. (Abstract) J of Interferon Research September 1994: Volume 14; Supplement 1: 151.
11. Gross G, Degen KW, Fierlbeck. G, Kowalzik L, Pfister H, **Roussaki A**, Schoefer H, Stetter C: Recombinant interferon gamma in anogenital warts: Results of a multicenter placebo-controlled clinical trial. Journal of Interferon Research November 1991; Vol.11; Supplement 1: S 76.
12. Gross G, **Roussaki A**. Recalcitrant giant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO2 laser Swift Lase™ and interferon beta gel. J Am Acad Dermatol 1997.
13. Jappe U, Müller M, de Villiers EM, Roussaki A, Gross G. HPV-11-L1-antibodies and HPV-DNA in children with anogenital warts and in their close contact persons. International Journal of STD & AIDS, August 2002, 13: 27.
14. Klimi E, **Roussaki A**. Granuloma annulare successfully treated with ointment containing 1% pimecrolimus. Pediatric Dermatology May/June 2004, 21 (3): 366-367.
15. **Roussaki-Schulze A**, Rallis E, Kouskoukis C, Nasiopoulou A, Arvanitis A, Zafiriou E. Topical treatment of patchy alopecia areata with a combination of minoxidil solution 5% and clobetasol propionate 0.05%: Journal of the European Academy of Dermatology & Venereology. 19:394, Nov 2005.
16. Tzanetakos C, Kourlaba G, Chatzikou M, Antoniou C, Ioannidis D, Petridis A, Rigopoulos D, **Roussaki-Schulze A**, Sotiriadis D, Maniadas N . Cost-effectiveness of

secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece. *Value in Health* Nov 2016, 19 (7), A569.

17. Mavropoulos A, Zafiriou E, Varna A, Papadopoulou E, Alexiou I, **Roussaki-Schulze AV**, Bogdanos DP, Sakkas LI. FRI0504 Apremilast expands IL-10-producing regulatory b cells, and decreases TH1 and TH7 cells in psoriatic arthritis and psoriasis. *Annals of the Rheumatic Diseases* June 2017, 76 (Suppl 2), 680-680.
18. Patrikiou E, Liaskos C, Zafiriou E, Efthymiou G, Scheper T, Meyer W, **Roussaki-Schulze A**, Sakkas LI, Bogdanos DP. AB0932 Helicobacter pylori antigen specific antibodies in psoriatic arthritis. *Annals of the Rheumatic Diseases* 2018, 77 (Suppl 2), 1591-1591.
19. Murrell D, Stavropoulos P, Patsatsi A, Zeeli T, Baum S, Bassukas I, Caux F, **Roussaki A**, Sinclair R, Kern J, Gourlay S, Joly P. LB1509 Anti-desmoglein levels & response to the BTK inhibitor PRN1008 in pemphigus. *Journal of Investigative Dermatology* 2018, 138 (9), B7.

CHAPTERS IN INTERNATIONAL BOOKS

- 1) Gross G, **Roussaki A**, Pfister H: Recurrent vulvar Buschke-Loewenstein's tumorlike condylomata acuminata and Hodgkin's disease effectively treated with recombinant Interferon-alpha-2c. *Gelas adjuvant to electrocautery*. In Fritsch P, Schuler G, Hinter (eds) *Immunodeficiency in Curr Probl. Dermatol.*, Basel Karger, 1989, Vol 18: 178-184.